Synthesis and evaluation of electrospun PCL-plasmid DNA nanofibers for post cancer treatments

No Thumbnail Available
Authors
Ceylan, Muhammet
Asmatulu, Ramazan
Jiang, Jianhao
Usta, Aybala
Jia, Tanghong
Yao, Li
Yang, Shang-You
Advisors
Issue Date
2022-08-12
Type
Article
Keywords
PCL , Plasmid DNA , Electrospun nanofibers , Biomedical applications
Research Projects
Organizational Units
Journal Issue
Citation
Ceylan, M., Asmatulu, R., Jiang, J., Usta, A., Jia, T., Yao, L., & Yang, S.-y. (2022). Synthesis and evaluation of electrospun PCL-plasmid DNA nanofibers for post cancer treatments. Materials Today: Proceedings. https://doi.org/https://doi.org/10.1016/j.matpr.2022.07.447
Abstract

Poly-?-caprolactone (PCL) incorporated with plasmid DNA was electrospun, and the resultant nanofibers were used to observe DNA release from the nanofibers. The plasmid DNA enhanced green fluorescent protein (EGFP) with cytomegalovirus (CMV) promoter (PCMVb-GFP) was amplified with E. coli. PCL was chosen because it is biodegradable aliphatic polyester, which plays a critical role in tissue engineering, such as scaffolding, drug, DNA, gene and protein delivery vehicles. Some of the physical and biological properties of the nanofibers were determined using different methods. Scanning electron microscopy (SEM) micrographs showed that nanofibers have an average diameter of about 100 nm. Cytotoxicity tests showed that cell viability for 1 day, 4 days, and 7 days of the tests were above 80 %. These data demonstrated that PCL-plasmid DNA nanofibers have no cytotoxicity and showed benign biocompatibility for biomedical applications. PCMVb-GFP plasmid-linked electrospun nanofibers continuously released double-stranded DNA for at least seven days. For the first 15 min, there was a burst release of about 1.8 ng/ml. For the following hours and days, the release was about to be the same (release of 0.575 ng/ml). Therefore, PCL nanofibers may be an ideal candidate for various biomedical applications such as cancer treatment, scaffolding, tissue engineering, and protein delivery vehicles. © 2022

Table of Contents
Description
Click on the DOI to access this article (may not be free).
Publisher
Elsevier
Journal
Book Title
Series
Materials Today: Proceedings
2022
PubMed ID
DOI
ISSN
2214-7853
EISSN